$8.20
2.37% today
Nasdaq, Feb 05, 04:19 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$8.01
-0.37 4.42% 1M
+2.64 49.16% 6M
-0.97 10.80% YTD
+0.46 6.09% 1Y
-9.61 54.54% 3Y
-11.43 58.80% 5Y
+4.66 139.10% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.20 2.56%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Market capitalization $1.15b
Enterprise Value $885.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 30.81
EV/Sales (TTM) EV/Sales 4.02
P/S ratio (TTM) P/S ratio 5.20
P/B ratio (TTM) P/B ratio 2.95
Revenue growth (TTM) Revenue growth 38.72%
Revenue (TTM) Revenue $220.36m
EBIT (operating result TTM) EBIT $-15.70m
Free Cash Flow (TTM) Free Cash Flow $28.76m
Cash position $348.75m
EPS (TTM) EPS $-0.16
P/E forward negative
P/S forward 4.87
EV/Sales forward 3.76
Short interest 5.25%
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
83%
Hold
17%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
220 220
39% 39%
100%
- Direct Costs 28 28
159% 159%
13%
192 192
30% 30%
87%
- Selling and Administrative Expenses 166 166
10% 10%
75%
- Research and Development Expense 23 23
54% 54%
10%
3.83 3.83
104% 104%
2%
- Depreciation and Amortization 20 20
175% 175%
9%
EBIT (Operating Income) EBIT -16 -16
83% 83%
-7%
Net Profit -23 -23
71% 71%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
14 days ago
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Positive
24/7 Wall Street
about 2 months ago
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Neutral
Business Wire
3 months ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 300
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today